PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
CRH plc (CRH)
114.271.68 (1.49%)
111.48 - 114.40
76.75 - 114.40
5.09M / 4.23M (Avg.)
23.96 | 4.77
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-23.83%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
-41.87%
Negative gross profit growth while CX is at 1.87%. Joel Greenblatt would examine cost competitiveness or demand decline.
-97.12%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-98.37%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-112.82%
Negative net income growth while CX stands at 1419.30%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-114.56%
Negative EPS growth while CX is at 1600.00%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-114.71%
Negative diluted EPS growth while CX is at 1600.00%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
-0.25%
Both firms reduce share counts. Martin Whitman would compare buyback intensity relative to free cash flow generation.
-1.02%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
5.91%
Maintaining or increasing dividends while CX cut them. John Neff might see a strong edge in shareholder returns.
-124.14%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-172.97%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
15.40%
10Y revenue/share CAGR at 50-75% of CX's 21.06%. Martin Whitman would question if the firm’s offerings lag behind the competitor.
15.40%
5Y revenue/share CAGR at 50-75% of CX's 26.83%. Martin Whitman would worry about a lagging mid-term growth trajectory.
15.40%
3Y revenue/share CAGR above 1.5x CX's 1.67%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
-7.82%
Negative 10Y OCF/share CAGR while CX stands at 5.82%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-7.82%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-7.82%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
-268.56%
Negative 10Y net income/share CAGR while CX is at 656.62%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-268.56%
Negative 5Y net income/share CAGR while CX is 1773.66%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-268.56%
Negative 3Y CAGR while CX is 289.17%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
12.03%
Below 50% of CX's 72.61%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
12.03%
Below 50% of CX's 59.48%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
12.03%
Equity/share CAGR of 12.03% while CX is zero. Bruce Berkowitz sees if minor gains can snowball into a bigger lead soon.
-64.08%
Cut dividends over 10 years while CX stands at 0.00%. Joel Greenblatt suspects a weaker ability to return capital vs. the competitor.
-64.08%
Negative 5Y dividend/share CAGR while CX stands at 0.00%. Joel Greenblatt sees a weaker commitment to dividends vs. a competitor that might be growing them.
-64.08%
Negative near-term dividend growth while CX invests at 0.00%. Joel Greenblatt sees a weaker short-term distribution policy unless justified by strategic spending.
6.66%
AR growth is negative/stable vs. CX's 57.91%, indicating tighter credit discipline. David Dodd confirms it doesn't hamper actual sales.
4.31%
Inventory growth well above CX's 4.79%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
2.58%
Similar asset growth to CX's 2.48%. Walter Schloss finds parallel expansions or investment rates.
-1.91%
We have a declining book value while CX shows 18.86%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
11.01%
We have some new debt while CX reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
No Data
No Data available this quarter, please select a different quarter.
-5.17%
We cut SG&A while CX invests at 0.60%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.